Home LiteratureArticle Details
PMID: 9186302 Published · ppublish English Clinical Trial Comparative Study Journal Article Research Support, Non-U.S. Gov't

Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus.

Metabolism: clinical and experimental ·Vol. 46 ·No. 6 ·1997-06-00 ·Pages 661-5

Berg TJ, Bangstad HJ, Torjesen PA, Osterby R, Bucala R, Hanssen KF

Abstract

The biochemical mechanisms that cause the development and progression of diabetic nephropathy are unknown. Advanced glycation end products (AGEs) might play a role, as shown by increased levels of tissue-bound and circulating AGEs that correlate with the severity of diabetic nephropathy. The aim of the present study was to investigate if circulating AGEs predict the progression of morphological pathology in patients with diabetic nephropathy. We have developed an immunoassay to determine serum levels of AGEs. In a prospective clinical trial of young insulin-dependent diabetes mellitus (IDDM) patients with microalbuminuria, kidney biopsies were taken at baseline and after 24 to 36 months. The biopsies were analyzed for structural changes in the glomeruli by quantitative morphometry (electron microscopy). We have retrospectively analyzed serum AGEs. The mean serum level of AGEs at the start of the study was 18.7 U/mL (95% confidence interval [CI], 16.9 to 20.5). A positive correlation between serum AGE levels at the start of study and changes from baseline to follow-up study in basement membrane thickness (r = .56, P < .02) and matrix/glomerular volume fraction (r = .57, P < .02) was demonstrated. In a stepwise regression analysis with changes in the matrix/glomerular volume fraction as the dependent variable, serum AGE levels at the start of the study proved to be a significant independent variable (P < .02), whereas the mean hemoglobin A1c (HbA1c) or HbA1c at the start was not. This study shows that serum AGEs predict the progression of early morphological kidney damage during 2.5 years in patients with IDDM.

MeSH Terms
Adolescent Adult Basement Membrane/pathology,ultrastructure Biomarkers/blood Child Confidence Intervals Diabetes Mellitus, Type 1/blood,pathology,physiopathology Diabetic Nephropathies/blood,pathology,physiopathology Disease Progression Fluorescent Antibody Technique Glycated Hemoglobin A/analysis Glycation End Products, Advanced/blood Humans Kidney/pathology,ultrastructure Kidney Glomerulus/pathology Microscopy, Electron Predictive Value of Tests Prospective Studies Reagent Strips Regression Analysis
Chemicals
Biomarkers Glycated Hemoglobin A Glycation End Products, Advanced Reagent Strips
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Berg T J
Aker Diabetes Research Centre, Aker University Hospital, Oslo, Norway.
Bangstad H J
Torjesen P A
Osterby R
Bucala R
Hanssen K F
Article Info
Journal
Metabolism: clinical and experimental
Abbr.
Metabolism
ISSN
0026-0495
Published
1997-06-00
Pages
661-5
Language
English
Region
United States
NLM ID
0375267
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com